Chewy Sinks 11% as Free Cash Flow Miss Overshadows Raised Outlook; Petco Falls 6%, Freshpet Ticks Up

Chewy shares fell 11% to $20.68 after fiscal Q2 free cash flow declined 15.5% year over year to $89.5 million, overshadowing revenue of $3.33 billion (+7.3% year over year, 0.4% above consensus) and in-line adjusted EPS of $0.36. Capital expenditures rose 71.1% to $47.9 million amid SmartPak integration and the $400 million Modern Animal acquisition, while management maintained roughly 80% full-year free-cash-flow conversion guidance and raised its fiscal 2026 sales outlook to $13.46-$13.57 billion. The selloff spread to Petco, down 6%, while Freshpet rose 0.41%, underscoring investor preference for fresh-food growth over Chewy's uncertain multiquarter reinvestment payoff.

Analysis

CHWY’s reset is fundamentally a valuation-of-cash-flow issue, not a demand issue: incremental growth is being directed into lower-visibility, more capital-intensive service categories rather than immediately accretive retail economics. That raises the probability that consensus EBITDA estimates remain intact while FCF estimates and the multiple applied to them fall. WOOF’s sympathy decline is directionally rational because it lacks CHWY’s recurring digital relationship and has materially less room to fund an investment cycle; competitive veterinary expansion could pressure its already-fragile store-level recovery over the next 6-18 months.

FRPT is the cleaner relative beneficiary because its growth is tied to premiumization and category mix rather than fulfillment or clinic buildout. The second-order risk is that fresh-food penetration increasingly requires refrigerated capacity at retail partners, creating execution and margin risk if growth decelerates; therefore FRPT should not be treated as a defensively insulated pet-sector long. Near term, the key CHWY catalyst is management’s ability to reconcile capex, acquisition/integration spending, and working-capital timing with the stated full-year cash-conversion target at the upcoming consumer-conference appearance and next earnings release.

Consensus may be too quick to equate reinvestment with permanent margin deterioration: a high-repeat customer base can make veterinary cross-sell economics attractive if cohorts show rising spend and retention. But that is not yet independently demonstrated in reported cash generation. A sustained CHWY recovery requires evidence that quarterly FCF conversion normalizes without another step-up in capex; otherwise the stock can remain cheap on earnings while continuing to de-rate on cash flow.

Key Decisions for Investors

• Maintain/establish a 1-3 month relative-value position: long FRPT / short CHWY in approximately beta-neutral dollar amounts. The trade captures premium-food growth versus uncertain cash conversion; reassess if CHWY demonstrates FCF conversion consistent with its full-year target or if FRPT lowers growth/margin guidance.
• Do not buy the initial CHWY drawdown outright before management provides a quantified capex and working-capital bridge. Upgrade to a tactical long only if commentary confirms no further upward capex revision and the next reported quarter shows sequential FCF recovery; downside risk remains a further multiple reset if cash conversion misses again.
• Remain underweight WOOF versus PAWZ over 6-12 months. Its recovery thesis is more exposed to price competition, veterinary labor/service investment, and fixed-store costs; cover the underweight if comparable-sales momentum meaningfully accelerates while leverage and liquidity trends improve.
• For existing FRPT longs, use a 3-6 month risk discipline around retail velocity and gross-margin progression rather than sector sentiment. Trim if fresh-food growth falls below its guided range or if margin expansion stalls, as the current relative resilience likely embeds continued premiumization.